Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2015

01.08.2015 | case report

Lung cancer in pregnancy

verfasst von: Kornelia Holzmann, Roland Kropfmüller, Herwig Schinko, Stephan Bogner, Franz Fellner, Wolfgang Arzt, Bernd Lamprecht

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

In the 26th week of gestation, a 29-year-old pregnant office employee was referred to the pulmonary department of Linz General Hospital (AKH) under the suspicion of tuberculosis. She complained of a cough with intermittent hemoptysis and pain in the thoracic spine from which she had been suffering the past 9 weeks. A plain chest X-ray showed a dense infiltrate on the right side and multiple smaller shadows in both lungs. Laboratory testing revealed anemia, leukocytosis, and an increase of C-reactive protein. All tests for tuberculosis were negative.
A bronchoscopy was performed and biopsies were taken from the right upper and middle lobe. The histopathological examination found cells of an adenocarcinoma. A magnetic resonance imaging (MRI) revealed a large tumor and surrounding atelectasis were seen in the right upper and middle lobe, as well as multiple intrapulmonary metastases in both lungs. In addition, not only metastases in the thoracic spine (level Th2/3) but also at other osseous locations and multiple cerebral metastases were detected. The patient received one cycle of chemotherapy consisting of docetaxel and carboplatin (AUC5) in the 27th week of gestation. Additional radiotherapy was applied to the involved thoracic spine. Due to positive epidermal growth factor receptor mutation, therapy with gefitinib 250 mg/day was started 2 days after a Caesarean section (preceded by treatment for fetal lung maturation). A healthy girl was delivered in the 30th week of pregnancy. Staging with computed tomography (CT) after delivery revealed an unstable fracture of Th2 with compression of the spinal cord. Neurosurgery was performed, consisting of a ventral corporectomy of Th1–2 followed by an anterior and posterior osteosynthesis for stabilization. The patient was discharged without neurological deficits within 1 week. Subsequent treatment with gefitinib improved the performance status of the patient, and CT scans of the chest and an MRI of the brain showed the size of the tumor to be shrinking. Meanwhile, the infant developed appropriately for her age.
After 14 months of the first diagnosis, the patient experienced neurological symptoms (aphasia, confusion) due to neoplastic meningeosis and cerebral venous sinus thrombosis together with local tumor progression in the lung. One course of chemotherapy, combining carboplatin/pemetrexed/bevacizumab, was given without clinical response. Despite best supportive care, the patient died 17 months after diagnosis in October 2013.
Literatur
2.
Zurück zum Zitat Statistics Austria, Austrian Cancer Registry, Lung Cancer Incidence (on September 13, 2011). Completed Sept. 29, 2011. Statistics Austria, Austrian Cancer Registry, Lung Cancer Incidence (on September 13, 2011). Completed Sept. 29, 2011.
3.
Zurück zum Zitat Azim HA Jr., Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010;67(3):251–6.CrossRefPubMed Azim HA Jr., Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010;67(3):251–6.CrossRefPubMed
4.
Zurück zum Zitat Hayama M, Chida M, Tamura M, Kobayashi S, Oyaizu T, Honma K. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann Thorac Carciovasc Surg. 2014;20:325–8.CrossRef Hayama M, Chida M, Tamura M, Kobayashi S, Oyaizu T, Honma K. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann Thorac Carciovasc Surg. 2014;20:325–8.CrossRef
5.
Zurück zum Zitat Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in post-menopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. The Lancet. 2009;374:1243–51.CrossRef Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in post-menopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. The Lancet. 2009;374:1243–51.CrossRef
6.
Zurück zum Zitat Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adencarcinoma of the lung. J Clin Oncol. 2009;27:411–7.CrossRefPubMed Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adencarcinoma of the lung. J Clin Oncol. 2009;27:411–7.CrossRefPubMed
7.
Zurück zum Zitat Traynor AM, Schiller JH, Stabile LP, et al. Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009;64:51–9.PubMedCentralCrossRefPubMed Traynor AM, Schiller JH, Stabile LP, et al. Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009;64:51–9.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008;113(11):3069–74.CrossRefPubMed Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008;113(11):3069–74.CrossRefPubMed
9.
Zurück zum Zitat Jänne PA, Rodriquez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy. Oncology. 2001;61(3):175–83.CrossRefPubMed Jänne PA, Rodriquez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy. Oncology. 2001;61(3):175–83.CrossRefPubMed
10.
Zurück zum Zitat Kim JH, Kim HS, Sung CW, Kim KH, Kim CH, Lee KY. Docetaxel, gemcitabine and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer. 2008;59(2):270–3.CrossRefPubMed Kim JH, Kim HS, Sung CW, Kim KH, Kim CH, Lee KY. Docetaxel, gemcitabine and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer. 2008;59(2):270–3.CrossRefPubMed
11.
Zurück zum Zitat Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs. 2013;15(5):329–34.CrossRefPubMed Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs. 2013;15(5):329–34.CrossRefPubMed
12.
Zurück zum Zitat Gurumurthy M, Koh P, Singh R, Bhide A, Satodia P, Hocking M, Anbarasu A, Wood LE. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. J Perinatol. 2009;29(1):63–5.CrossRefPubMed Gurumurthy M, Koh P, Singh R, Bhide A, Satodia P, Hocking M, Anbarasu A, Wood LE. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. J Perinatol. 2009;29(1):63–5.CrossRefPubMed
13.
Zurück zum Zitat Carcía-González J, Cueva J, Lamas MJ, Curiel T, Krana B, López-López R. Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. Clin Transl Oncol. 2008;10(6):375–6.CrossRef Carcía-González J, Cueva J, Lamas MJ, Curiel T, Krana B, López-López R. Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. Clin Transl Oncol. 2008;10(6):375–6.CrossRef
14.
Zurück zum Zitat Kluetz PG, Edelman MJ. Successful treatment of small cell lung cancer during pregnancy. Lung Cancer. 2008;61(1):129–30.CrossRefPubMed Kluetz PG, Edelman MJ. Successful treatment of small cell lung cancer during pregnancy. Lung Cancer. 2008;61(1):129–30.CrossRefPubMed
15.
Zurück zum Zitat Rivas G, Llinás N, Bonilla C, Rubiano J, Cuello J, Arango N. Use of erlotinib throughout pregnancy: a case report of patient with metastatic lung adenocarcinoma. Lung Cancer. 2012;77(2):469–72.CrossRefPubMed Rivas G, Llinás N, Bonilla C, Rubiano J, Cuello J, Arango N. Use of erlotinib throughout pregnancy: a case report of patient with metastatic lung adenocarcinoma. Lung Cancer. 2012;77(2):469–72.CrossRefPubMed
16.
Zurück zum Zitat Zambelli A, Prada GA, Fregoni V, Ponchio L, Sagrada P, Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung Cancer. 2008;60(3):455–7.CrossRefPubMed Zambelli A, Prada GA, Fregoni V, Ponchio L, Sagrada P, Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung Cancer. 2008;60(3):455–7.CrossRefPubMed
17.
Zurück zum Zitat Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34(4):302–12.CrossRefPubMed Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34(4):302–12.CrossRefPubMed
Metadaten
Titel
Lung cancer in pregnancy
verfasst von
Kornelia Holzmann
Roland Kropfmüller
Herwig Schinko
Stephan Bogner
Franz Fellner
Wolfgang Arzt
Bernd Lamprecht
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0726-6

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen